About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Monthly Archives: April 2006
Weekly Roundup – 4/29/06
As part of a new feature, I’ve designated Friday’s as mop-up time – a review of what happened during the week with handy links to the sources. GAO Issues Review of FDA on Safety – Unless you had been living … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup – 4/29/06
Making Lemons out of Lemonade – When Good News Still Sounds Bad
Well, there was good news and there was bad news. A few years back, a story in USA Today revealed that a large number of FDA Advisory Committee members had financial ties to the industry. It was, if I recall, … Continue reading
Posted in FDA Image, Pharma Industry Image
Comments Off on Making Lemons out of Lemonade – When Good News Still Sounds Bad
The Cost to Public Image of Delayed Generics
Yesterday there was an article carried in the Washington Post stating that, according to an FTC report, brand name drug companies are increasingly prone to reaching deals with generic companies to delay their entry onto the market. In essence, a … Continue reading
Posted in Pharma Industry Image
2 Comments
Psychiatry, DSM and Drug Companies
There has recently been a lot of hullabaloo about the fact that a large number of psychiatrists associated with writing the guidelines contained in the DSM manual have had past connections to drug companies according to recent reports. I am … Continue reading
Posted in Pharma Industry Image
1 Comment
My Take on the Toke – The FDA, Marijuana, Plan B, Politics and Bad Communications
Last week, the FDA issued a statement to the effect that marijuana has no medical value. Unfortunately, the FDA’s credibility on scientific decisions that have political issues associated with them has been wantonly squandered by agency’s inaction on the RX-OTC … Continue reading
Posted in FDA Image, FDA Policy
1 Comment